

6. LITERATURVERZEICHNIS

1. Jevons MP. „Celbenin“-resistant staphylococci. Br Med J 1961;1:124-5
2. Barber M. Methicillin resistant staphylococci. J Clin Path 1961;14:385-93
3. Barrett FF, McGehee RF, Finland M. Methicillin-resistant *Staphylococcus aureus* at Boston city Hospital. Bacteriologic and Epidemiologic observations. N Eng J Med 1968; 279(9):441-8
4. Voss A, Milatovic D, Wallrauch Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant *Staphylococcus aureus* in Europe. Eur J Clin Microbiol Infect Dis 1994;13(1):50-5
5. Hryniewicz W. Epidemiology of MRSA. Infection 1999;27 Suppl 2:S13-6
6. Ayliffe GAJ. The progressive intercontinental spread of methicillin resistant *Staphylococcus aureus*. Clin Infect Dis 1994;24 Suppl 1:S74-9
7. Boyce JM. Increasing prevalence of methicillin-resistant *Staphylococcus aureus* in the United States. Infect Control Hosp Epidemiol 1990;11:639-42
8. Haley RW, Hightower AW, Khabbaz RF, Thornsberry C, Martone WJ, Allen JR et al. The emergence of methicillin-resistant *Staphylococcus aureus* infections in United States hospitals. Possible role of the house staff-patient transfer circuit. Ann intern Med 1998;97(3):297-308
9. Kresken M, Hafner D, Witte W, Reinert RR. Resistenzentwicklung bei Staphylokokken und anderen grampositiven Erregern gegenüber Chemotherapeutika im mitteleuropäischen Raum. Chemother J 1999;8:136-45
10. Kresken M, Hafner D. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa. Chemother J 2000;9:51-86
- 11.11. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. PEG Resistenzstudie 2001. Resistenzsituation bei klinisch wichtigen Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenzen der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2001.
- 13.12. <http://www.earss.rivm.nl/>
13. Tiemersma ET, Bronzwaer S, Lytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N et al. Methicillin-resistant *Staphylococcus aureus* in Europe, 1999-2002. Emerg Infect Dis 2004;10 (9):1627-34

14. Rüdén H, Gastmeier P, Daschner F, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of the first national prevalence study (NIDEP). *Infection* 1997;25(4):199-202
15. Fridkin SC, Gaynes P. Antimicrobial resistance in intensive care units. *Clin Chest Med* 1999; 20(2):303-16
16. Gastmeier P, Geffers C, Sohr D, Schwab F, Behnke M, Rüdén H. Surveillance nosokomialer Infektionen in Intensivstationen: Aktuelle Daten und Interpretationen. *Wien Klin Wochenschr* 2003;115(3-4):99-103
17. Chambers HF. Methicillin Resistance in Staphylococci: Molecular and biochemical basis and clinical implications. *Clin Microbiol Rev* 1997;10(4):781-91
18. Kreiswirth B, Kornblum J, Arbeit RD, Eisner W, Maslow JN, McGeer A et al. Evidence for a clonal origin of methicillin resistance in *Staphylococcus aureus*. *Science* 1993; 259(5092): 227-30
19. Levine JF. Vancomycin: a review. *Med Clin North Am* 1987;71(6):1135-45
20. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. *Clin Pharmacokinet* 1986;11(4):257-82
21. Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M et al. Emergence in Asian Countries of *Staphylococcus aureus* with Reduced Susceptibility to Vancomycin. *Antimicrob Agents Chemother* 2004;48:4926-8
22. Guerin F, Buu-Hoi A, Mainardi J-L, Kac G, Colardella N, Vaupré S et al. Outbreak of methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to glycopeptides in a Parisian hospital. *J Clin Microbiol* 2000;38(8):2985-8
23. Anonymous. Reduced susceptibility of *Staphylococcus aureus* to vancomycin-Japan, 1996. *MMWR* 1997;46(27):624-6
24. Hiramatsu K. The emergence of *Staphylococcus aureus* with reduced susceptibility to vancomycin in Japan. *Am J Med* 1998;104(5A):S-10S
25. Anonymous. *Staphylococcus aureus* with reduced susceptibility to vancomycin- United States, 1997. *MMWR* 1997;46(33):765-9
26. Hamilton-Miller JM. Vancomycin-resistant *Staphylococcus aureus*: a real and present danger? *Infection* 2002;30(3):118-24
27. Chang S, Sievert SM, Hageman JC, Boulton ML, Tenover FC, Downes FP et al. Infection with Vancomycin-resistant *Staphylococcus aureus* containing the *vanA* resistance Gene. *N Engl J Med* 2003; 348:1342-7

28. Werner G, Cuny C, Schmitz F-J, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant *Staphylococcus aureus* with reduced sensitivity to glycopeptides. *J Clin Microbiol* 2001;39(10):3586-90
29. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L et al. Linezolid resistance in a clinical isolate of *Staphylococcus aureus*.
30. Working Party Report. Revised guidelines for the control of methicillin-resistant *Staphylococcus aureus* infection in hospitals. *J Hosp Infect* 1998; 39:253-290
31. Hershov RC, Khayr WF, Smith NL. A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* infections in a university hospital. *Infect Control Hosp Epidemiol* 1992;13:587-93
32. Keane CT, Coleman DC, Cafferkey MT. Methicillin-resistant *Staphylococcus aureus*- a reappraisal. *J Hosp Infect* 1991;19:147-52
33. Boyce JM. Should we vigorously try to contain and control methicillin-resistant *Staphylococcus aureus*? *Infect Control Hosp Epidemiol* 1991;12:46-54
34. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchner AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteraemia: a meta-analysis. *Clin Infect Dis* 2003; 36:53-9
35. Whitby M, McLaws M-L, Berry G. Risk of death from methicillin resistant *Staphylococcus aureus* bacteraemia: a meta-analysis. *Med J Aust* 2001;175(5):264-7
36. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SJ et al. Adverse Clinical and economic outcomes attributable to methicillin resistance among patients with surgical site infection. *Clin Infect Dis* 2003;36:592-8
37. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of *Staphylococcus aureus* infection in New York City hospitals. *Emerg Infect Dis* 1999;5(1):9-17
38. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* primary bacteremia: at what costs? *Infect Control Hosp Epidemiol* 1999;20:408-11
39. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant *Staphylococcus aureus*. A cost-benefit analysis in an intensive care unit. *JAMA* 1999;282(18):1745-51
40. Jarvis W. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost and prevention. *Infect Control Hosp Epidemiol* 1996;17:552-7

41. Boyce JM, White RL, Spruill EY. Impact of methicillin-resistant *Staphylococcus aureus* on the incidence of nosocomial staphylococcal infections. *J Infect Dis* 1983;148(4):763
42. Jernigan JA, Clemence MA, Stott GA, Titus MG, Alexander CH, Palumbo M et al. Control of methicillin-resistant *Staphylococcus aureus* at a university hospital: one decade later. *Infect Control Hosp Epidemiol* 1995;16(12): 686-96
43. Stamm AM, Long MN, Belcher B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant *Staphylococcus aureus*. *Am J Infect* 1993; 21:70-4
44. Chambers HF. The changing epidemiology of *Staphylococcus aureus*? *Emerg Infect Dis* 2001;7(2):178-82
45. Peacock JE Jr, Marsik FJ, Wenzel RP. Methicillin resistant *Staphylococcus aureus*: Introduction and spread within a hospital. *Ann Intern Med* 1980;93(4):526-32
46. Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, John JF, Korvick JA et al. Methicillin-resistant *Staphylococcus aureus*: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. *Am J Med* 1993; 94: 313-28
47. Jernigan J, Titus MG, Gröschel DHM, Getchell-White SI, Farr BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant *Staphylococcus aureus*. *Am J Epidemiol* 1996; 143: 496-504
48. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM et al. SHEA Guideline für preventing nosocomial transmission of multidrug-resistant strains of *Staphylococcus aureus* and Enterococcus. *Infect Control and Hosp Epidemiol* 2003;24(5):362-86
49. Kommission für Krankenhaushygiene und Infektionsprävention. Empfehlung zur Prävention und Kontrolle von Methicillin-resistenten *Staphylococcus aureus*-Stämmen (MRSA) in Krankenhäusern und anderen medizinischen Einrichtungen. *Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz* 1999;42(12):954-958
50. Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften. Maßnahmen beim Auftreten multiresistenter Erreger (MRE).
<http://www.uni-duesseldorf.de/AWMF/>
51. Samad A, Banerjee D, Carbarns N, Ghosh S. Prevalence of methicillin-resistant *Staphylococcus aureus* colonization in surgical patients, on admission to a Welsh hospital. *J Hosp Infect* 2002;51:43-46

52. Corea E, de Silva T, Perera J. Methicillin-resistant *Staphylococcus aureus*: prevalence, incidence and risk factors associated with colonization in Sri Lanka. *J Hosp Infect* 2003;55:145-148
53. Troillet N, Yehuda C, Samore MH, Dakos J, Eichelberger K, De Girolami PC et al. Carriage of methicillin-resistant *Staphylococcus aureus* at hospital admission. *Infect Control Hosp Epidemiol* 1998;19:181-5
54. Eveillard M, Ernst C, Cuviller S, Lescure FX, Malpaux M, Defouilloy I. Prevalence of methicillin-resistant *Staphylococcus aureus* carriage at the time of admission in two geriatric wards. *J Hosp Infect* 2002; 50: 122-6
55. Lucet JC, Chevret S, Durand-Zaleski I, Chastang C, Régnier B. Prevalence and risk factors for carriage of methicillin-resistant *Staphylococcus aureus* at admission to the intensive care unit. *Arch Intern Med* 2003; 163: 181-8
56. Guideline of the Working Party Infection Prevention No. 35a. Management policy for methicillin resistant *Staphylococcus aureus*.
57. Ministry of Health New Zealand. Guidelines for the control of methicillin-resistant *Staphylococcus aureus* in New Zealand.
58. Wagenvoort JHT. Dutch measures to control MRSA and the expanding European Union. *Eurosurveillance* 2000;5:26-8
59. Talon DR, Bertrand X. Methicillin-resistant *Staphylococcus aureus* in geriatric patients: usefulness of screening in a chronic-care setting. *Infect Control Hosp Epidemiol* 2001; 22:505-9
60. Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high-risk patients for methicillin-resistant *Staphylococcus aureus* on admission to the hospital: is it cost effective? *Infect Control Hosp Epidemiol* 1999; 20: 473-7
61. Eveillard M, Lancien E, Barnaud G, Hidri N, Gaba S, Benlolo JA. Impact of screening for MRSA carriers at hospital admission on risk-adjusted indicators according to the imported MRSA colonization pressure. *J Hosp Infect* 2005;59:254-258
62. Girou E, Azar J, Wolkenstein P, Cizeau F, Brun-Buisson C, Roujeau JC. Comparison of systematic versus selective screening for methicillin-resistant *Staphylococcus aureus* carriage in a high risk dermatology ward. *Infect Control Hosp Epidemiol* 2000; 21: 583-7
63. Cookson B. Is it time to stop searching for MRSA ? Screening is still important. *BMJ* 1997;314:664-5
64. Teare EL, Barrett SP. Is it time to stop searching for MRSA? Stop the ritual of tracing colonised people. *BMJ* 1997;314:665-7

65. Farrington M, Redpath C, Trundle C, Brown N. Controlling MRSA. *J Hosp Infect* 1999;41:251-2
66. Rahman M. Learning to live with MRSA. *Postgrad Med J* 1998;74:385-6
67. Rubinovitch B, Pittet D. Screening for methicillin resistant *Staphylococcus aureus* in the endemic hospital: what have we learned? *J Hosp Infect* 2001;47:9-18
68. Scudeller L, Leoncini O, Boni S, Navarra A, Rezzani A, Verdiriose S et al. MRSA carriage: the relationship between community and healthcare setting. A study in an Italian hospital. *J Hosp Infect* 2000 Nov; 46:222-29
69. Que TL, Ho PL, Yip KT, NG HL, Leung FY, Lai KK et al. Three year study of targeted screening for methicillin-resistant *Staphylococcus aureus* at hospital admission. *Eur J Clin Microbiol Infect Dis* 2003; 22: 268-70
70. Scriven JM, Silva P, Swann RA, Thompson MM, Naylor AR, Bell PRF et al. The acquisition of methicillin-resistant *Staphylococcus aureus* (MRSA) in vascular patients. *Eur J Vas Endovas Surg* 2003;25;147-51
71. Walsh TJ, Vlahov D, Hansen SL, Sonnenberg E, Khabbaz R, Gadacz T et al. Prospective microbiologic surveillance in control of nosocomial methicillin-resistant *Staphylococcus aureus*. *Infect Control* 1987;8(1):7-14
72. Pittet D, Safran E, Harbarth S, Borst F, Copin C, Rohner P et al. Automatic alerts for methicillin-resistant *Staphylococcus aureus* surveillance and control: role of a hospital information system. *Infect Control Hosp Epidemiol* 1996;17:496-502
73. Hoefnagels-Schuermans A, Borremans A, Peetermans W, Van Lierde S, Reybrouck G, Van Eldere J. Origin and transmission of methicillin-resistant *Staphylococcus aureus* in an endemic situation: differences between geriatric and intensive-care patients. *J Hosp Infect* 1997;36:209-22
74. Marshall C, Harrington G, Wolfe R, Fairley CK, Wesselingh S, Spelman D. Acquisition of methicillin-resistant *Staphylococcus aureus* in a large intensive care unit. *Infect Control Hosp Epidemiol* 2003;24:322-6
75. Murray-Leisure KA, Geib SG, Graceley D, Rubin-Slutsky AB, Saxena N, Muller HA et al. Control of epidemic methicillin-resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* 1990;11:343-50
76. Girou E, Pujade G, Legran P, Cizeau F, Brun-Buisson C. Selective screening for carriers for control of methicillin-resistant *Staphylococcus aureus* (MRSA) in high-risk hospital areas with a high level of endemic MRSA. *Clin Infect Dis* 1998;27:543-50

77. Merrer J, Santoli F, Appéré-De Vecchi C, Tran B, De Jonghe B, Outin H. „Colonization pressure“ and risk of acquisition of methicillin-resistant *Staphylococcus aureus* in a medical intensive care unit. *Infect Control Hosp Epidemiol* 2000;21(11):718-23
78. Pan A, Carnevale G, Catenazzi P, Colombini P, Crema L, Dolcetti L. Trends in methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infections: effect of the MRSA “search and isolate“ strategy in a hospital in Italy with hyperendemic MRSA. *Infect Control Hosp Epidemiol* 2005;26(2):127-33
79. Shanson DC, Johnstone D, Midgley J. Control of a hospital outbreak of methicillin-resistant *Staphylococcus aureus* infections: value of an isolation unit. *J Hosp Infect* 1985;6(3):285-92
80. Blumberg LH, Klugman KP. Control of methicillin-resistant *Staphylococcus aureus* bacteraemia in high-risk areas. *Eur J Clin Microbiol Infect Dis* 1994;13(1):82-85
81. Duckworth GJ, Lothian JLE, Williams JD. Methicillin-resistant *Staphylococcus aureus*: Report of an outbreak in a London teaching hospital. *J Hosp Infect* 1988;11:1-15
82. Coello R, Jiménez J, García M, Arroyo P, Minguez D, Fernández C et al. Prospective study of infection, colonization and carriage of methicillin-resistant *Staphylococcus aureus* in an outbreak affecting 990 patients. *Eur J Clin Microbiol Infect Dis* 1994;13:74-81
83. Farrington M, Redpath C, Trundle C, Coomber S, Brown NM. Winning the battle but losing the war: methicillin-resistant *Staphylococcus aureus* (MRSA) infection at a teaching hospital. *QJM* 1998;(8):539-48
84. Harbarth S, Martin Y, Rohner P, Henry N, Auckenthaler R, Pittet D. Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant *Staphylococcus aureus*. *J Hosp Infect* 2000;46:43-49
85. Herwaldt LA. Control of methicillin resistant *Staphylococcus aureus* in the hospital setting. *Am J Med* 1999;106:11-18
86. Längen, Lauterbach: DRG in deutschen Krankenhäusern, Stuttgart 2003
87. RKI. Liste der vom Robert-Koch-Institut geprüften und anerkannten Desinfektionsmittel und -verfahren. *Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz* 2003;1:74-95
88. Tarzi S, Kennedy P, Stone S, Evans M. Methicillin-resistant *Staphylococcus aureus*: psychological impact of hospitalization and isolation in an older adult population. *J Hosp Infect* 2001;49:250-254
89. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci USA* 2002;99(11):7687-92

90. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988;16:128-40
91. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. *Infect Control Hosp Epidemiol* 1992;13:606-8
92. Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen: Handbuch für die Surveillance von nosokomialen Infektionen nach den Methoden des Krankenhaus-Infektions-Surveillance-Systems KISS, Schriftenreihe des Bundesministeriums für Gesundheit Band 142, Baden-Baden 2002.
93. Wakefield DS, Pfaller M, Massanari M, Hammons GT. Variation in methicillin-resistant *Staphylococcus aureus* occurrence by geographic location and hospital characteristics. *Infect Control* 1987;8(4):151-7
94. Morgan M, Evans-Williams D, Salmon R, Hosein I, Looker DN, Howard A. The population impact of MRSA in a country: the national survey of MRSA in Wales, 1997. *J Hosp Infect* 2000;44:227-39
95. Roethlisberger, Dickinson: Management and the Worker, Cambridge 1939
96. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant *Staphylococcus aureus* in Canadian hospitals. *Infect Control Hosp Epidemiol* 2001;22:99-104
97. Coelleo R, Glynn JR, Gaspar C, Picazo JJ, Fereres J. Risk factors for developing clinical infection with methicillin-resistant *Staphylococcus aureus* (MRSA) amongst hospital patients initially only colonized with MRSA. *J Hosp Infect* 1997;37:39-46
98. Pujol M, Pena C, Pallares R, Ayats J, Ariza J, Gudiol F. Risk factors for nosocomial bacteraemia due to methicillin-resistant *Staphylococcus aureus*. *Eur J Clin Microbiol Infect Dis* 1994;13:96-102
99. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R. Methicillin-resistant *Staphylococcus aureus* and antimicrobial use in Belgian hospitals. *Infect Control Hosp Epidemiol* 1999; 20(1):31-6
100. Monnet DL, Frimodt-Møller N. Antimicrobial-drug use and methicillin-resistant *Staphylococcus aureus*. *Emerg Infect Dis* 2001;7(1):161-3
101. Monnet DL. Methicillin-resistant *Staphylococcus aureus* and its relationship to antimicrobial use: possible implications for control. *Infect Control Hosp Epidemiol* 1998;19:552-9
102. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanism, and associated risks. *Clin Microbiol Rev* 1997;10(3):505-20

103. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1999;43(6):1412-6
104. Larson E, Kretzer K. Compliance with handwashing and barrier precautions. *J Hosp Infect* 1995; 30(Suppl):88-106
105. Pittet D, Hugonnet S, Harbarth S, Mouougla P, Sauvan V, Touveneau S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *Lancet* 2000; 356:1307-12
106. Rosdahl VT, Knudsen AM. The decline of methicillin resistance among Danish *Staphylococcus aureus* strains. *Infect Control Hosp Epidemiol* 1991;12:83-8
107. Wischniewski N, Kampf G, Gastmeier P, Schlingmann J, Schumacher M, Daschner F et al. Nosocomial wound infections: a prevalence study and analysis of risk factors. *Int Surg* 1998;83:93-7
108. von Baum H, Schmidt C, Svoboda D, Bock-Hensley O, Wendt C. Risk factors for methicillin-resistant *Staphylococcus aureus* carriage in residents of German nursing homes. *Infect Control Hosp Epidemiol* 2002;23(9):511-15
109. Heudorf U, Brumer V; Heuck D, Brume I, Wichelhaus TA. MRSA-Prävalenz bei Bewohnern von Alten- und Pflegeheimen sowie bei Patienten einer geriatrischen Rehabilitationsklinik. *HygMed* 2002;27(1/2):16-19
110. Heuck D, Witte W. Methicillin-resistente *Staphylococcus aureus* (MRSA) in deutschen Alten- und Pflegeheimen- zur Situation. *Epidemiologisches Bulletin* 2002;19:145-148
111. Goettsch W, Guebbels E, Wannet W, Hendrix MGR, Wagenvoort JHT, de Neeling AJ. MRSA in nursing homes in the Netherlands 1989 to 1998: a developing reservoir? *Eurosurveillance* 2000;5:28-31
112. Bradley SF. Methicillin-resistant *Staphylococcus aureus* in nursing homes. *Epidemiology, prevention and management. Drugs Aging* 1997;10(3):185-98
113. Fraise AP, Mitchell K, O'Brien SJ, Oldfield K, Wise R. Methicillin-resistant *Staphylococcus aureus* (MRSA) in nursing homes in a major UK city: an anonymized point prevalence survey. *Epidemiol Infect* 1997;118:1-5
114. O'Sullivan NP, Keane CT. Risk factors for colonization with methicillin-resistant *Staphylococcus aureus* among nursing home residents. *J Hosp Infect* 2000;45:206-10
115. Seto WH. Staff compliance with infection control practises: application of behavioural sciences. *J Hosp Infect* 1995;30(Suppl):107-15

116. Hicks NR, Moore E P, Williams EW. Carriage and community treatment of methicillin resistant *Staphylococcus aureus*: What happens to colonized patient after discharge ? J Hosp Infect 1991; 19: 17-24
117. Frénay HME, Vandenbroucke-Grauls CMJE, Molkenboer MJCH, Verhoef J. Long-term carriage and transmission of methicillin-resistant *Staphylococcus aureus* after discharge from hospital. J Hosp Infect 1992; 2: 207-215
118. Sanford MD, Widmer AF, Ale MJ, Jones RN, Wenzel RP. Efficient detection and long-term persistence of the carriage of methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis 1994; 19:1123-8
119. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC. Duration and risk of colonization by methicillin-resistant *Staphylococcus aureus* after hospital discharge and factors for prolonged carriage. Clin Infect Dis 2001; 32:1393-1398
120. MacKinnon MM, Allen KD. Long-term MRSA carriage in hospital patients. J Hosp Infect 2000;46:216-21
121. Kipp F, Becker K, Peters G, Eiff C. Evaluation of Different Methods To Detect Methicillin Resistance in Small-Colony Variants of *Staphylococcus aureus*. J Clin Microbiol 2004; 42(3): 1277-79
122. Kunori T, Cookson B, Roberts JA, Stone S, Kibbler C. Cost-effectiveness of different MRSA screening methods. J Hosp Infect 2002;51(3):189-200
123. Linnemann CC Jr, Mason M, Moore P, Korfhagen TR, Staneck JL. Methicillin-resistant *Staphylococcus aureus*: experience in a general hospital over four years. Am J Epidemiol 1982;115(6):941-50
124. Tam AY, Yeung CY. The changing pattern of severe neonatal staphylococcal infection: a 10-year study. Aust Paediatr J 1988;24(5):275-9
125. Pavillard R, Harvey K, Douglas D, Hewstone A, Andrew J, Collopy B et al. Epidemic of hospital-acquired infection due to methicillin-resistant *Staphylococcus aureus* in major Victorian hospitals. Med J Aust. 1982;1(11):451-4
126. Arnold, Michael: Krankenhaus-Report 2002, Stuttgart 2003
127. Rupp ME, Fey PD. Extended spectrum β -lactamase (ESBL)-producing enterobacteriaceae. Drugs 2003;63(4):353-65
128. Stone PW, Larson E, Kowar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002;30(3):145-52

129. Wernitz M, Veit S. Der Einfluß von MRSA auf die deutsche Volkswirtschaft. *Management und Krankenhaus* 2005;5: in press
130. Yamauchi M. Japan struck by resistant *S aureus*. *BMJ* 1993;306:740
131. Wagenvoort JHT. Eindämmung einer eineinhalbjährigen MRSA-III-29-Epidemie. *Hyg Med* 1997;22(6):314-30
132. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. *JAMA* 2003;290(14):1899-1905